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Abstract
In this contribution I critically revise the alchemical reversible approach in the context of the
statistical mechanics theory of non covalent bonding in drug receptor systems. I show that most
of the pitfalls and entanglements for the binding free energies evaluation in computer simulations
are rooted in the equilibrium assumption that is implicit in the reversible method. These critical
issues can be resolved by using a non-equilibrium variant of the alchemical method in molecular
dynamics simulations, relying on the production of many independent trajectories with a continuous
dynamical evolution of an externally driven alchemical coordinate, completing the decoupling of
the ligand in a matter of few tens of picoseconds rather than nanoseconds. The absolute binding
free energy can be recovered from the annihilation work distributions by applying an unbiased
unidirectional free energy estimate, on the assumption that any observed work distribution is
given by a mixture of normal distributions, whose components are identical in either direction of
the non-equilibrium process, with weights regulated by the Crooks theorem. I finally show that the
inherent reliability and accuracy of the unidirectional estimate of the decoupling free energies, based
on the production of few hundreds of non-equilibrium independent sub-nanoseconds unrestrained
alchemical annihilation processes, is a direct consequence of the funnel-like shape of the free energy
surface in molecular recognition. An application of the technique on a real drug-receptor system
is presented in the companion paper.
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INTRODUCTION
The determination of the binding affinity of a ligand for a biological receptor system
is placed right at the start of the drug discovery and development process, in a sequence
of increasing capital-intensive steps, from safety tests, lead optimization, preclinical and
clinical trials. Thanks to modern experimental and computational techniques, the cost for
screening putative ligands for a given protein target has diminished steadily in the last
decades. Regrettably, this increased productivity in ligands screening did not translate in
a corresponding surge in the rate of approved drugs.[1] It is becoming increasingly clear
that the observed decline in the R&D productivity in the pharmaceutical industry in the
last decades, the so-called Eroom Law,[2] is largely due to the high cost of failures at some
stage along the drug development sequence. Paradoxically, the screening capabilities in High
throughput screening or computer-based de novo techniques, by letting many candidates to
proceed further in the drug discovery pipeline, unavoidably produces a sharp increase in
the cost of failure.[3] From a computational standpoint, structure based virtual screening
using molecular docking technologies is definitely part of the problem.[4, 5] The reliability
of the common docking scoring functions regarding the affinity of a ligand for a target is
severely undermined by factors such as the complete or partial neglect of protein reorgani-
zation, microsolvation phenomena, entropic effects, ligand conformational disorder etc.[6, 7]
The simplifying assumptions implied in molecular docking, while speeding up the screening
process, have in general a strong negative impact on the predictive power of the method
that is often unable to discriminate between ligands of nanomolar, micromolar or millimolar
affinity[5, 7] hence producing a large number of costly false positive.
In the last two decades, in the context of atomistic molecular dynamics (MD) simulations
with explicit solvent, various computational techniques have been devised to compute the
absolute binding free energies with unprecedented accuracy such as the Double Decoupling
method (DDM),[8] Potential of Mean Force (PMF)[9, 10], Metadynamics[11–13] or general-
ized ensemble approaches (GE) like the Binding Energy Distribution Analysis (BEDAM)[14],
the Adaptive Integration Method[15], or the Energy Driven Undocking scheme.[16] All these
methodologies bypass the sampling limitations that are inherent to classical molecular dy-
namics simulations in drug receptor systems by appropriately modifying the interaction
potential and/or by invoking geometrical restraints so as to force the binding/unbinding
2
event in a simulation time scale typically in the order of the nanoseconds.[7, 17] In the
so-called alchemical transformations[8, 17–24], probably the most popular and widely used
[19, 25] of these methods, the ligand, in two distinct thermodynamic processes, is reversibly
decoupled from the environment in the bulk solvent and in the binding site of the solvated
receptor. Reversible decoupling is implemented by discretizing the non physical alchemical
path in a series of independent equilibrium simulations each with a different Hamiltonian
H(λi) with the ligand-environment coupling λi parameter varying in small steps from λ = 1
to λ = 0 corresponding to the fully coupled and decoupled (gas-phase) state of the lig-
and, respectively. In most of the variants of the reversible alchemical route, a geometrical
restraint, whose spurious contribution to the binding free energy may be eliminated a poste-
riori, keeps the ligand in the binding site at intermediate values of the λ coupling parameter.
The overall free energies for the two decoupling processes are computed by summing up the
free energies differences relative to λ-neighboring Hamiltonians using either thermodynamic
integration[26] (TI) or the free energy perturbation[27] (FEP) scheme with the Bennett ac-
ceptance ratio.[28–30] The absolute standard binding free energy can be finally computed as
the free energy difference between the two decoupling process[18] using a correction[8, 31, 32]
to account for the reversible work needed to bring the ligand volume from that imposed in
the MD simulation to that of the standard state. The alchemical procedure can be merged
with GE approaches by letting λ hopping between neighboring λ states so as to favor con-
formational sampling of the ligand.[6, 14, 22, 33]
In this contribution I critically revise the alchemical reversible approach in the context of
the statistical mechanics theory of non covalent bonding in drug receptor systems, evidenc-
ing the strengths and the weakness of the methodology from a computational standpoint.
For example, although the alchemical approach to the binding free energy determination can
be effectively parallelized, still, due to unpredictable convergence problems that may emerge
at the non physical intermediate λ states, the CPU cost per ligand-receptor pair remains
considerable,[21, 22, 33–35] with a non negligible share[7, 17, 34] of the overall parallel sim-
ulation time being invested in equilibration. Besides, minimizing the free energy variance in
reversible λ-hopping alchemical simulations without degrading excessively the performances
is far from trivial.[6, 33, 36]
We then rationalize the equilibrium unrestrained alchemical transformations, the so-called
Double Annihilation method (DAM) by W.L. Jorgensen and C. Ravimohan[18], as a limiting
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case of a general non equilibrium (NE) theory of alchemical processes, specifically addressing
some controversial and elusive issues like the volume dependence of the decoupling free
energy of the bound state.[31, 34, 37] We further show that most of pitfalls and entanglements
in the equilibrium approach can be resolved by using the recently proposed non-equilibrium
variant of the alchemical method, named Fast Switching Double Annihilation Method (FS-
DAM)[38] relying on the production of many independent non-equilibrium trajectories with a
continuous dynamical evolution of an externally driven alchemical coordinate,[39] completing
the alchemical decoupling of the ligand in a matter of few tens of picoseconds rather than
nanoseconds. The absolute binding free energy is recovered from the annihilation work
distributions by applying an unidirectional free energy estimate, on the assumption that
any observed work distribution is given by a mixture of Gaussian distributions,[32] whose
normal components are identical in either direction of the non-equilibrium process, with
weights regulated by the Crooks theorem.[40] In FS-DAM, the sampling issue at intermediate
λ state is eliminated altogether. The accuracy in FS-DAM free energy computation relies on
the correct sampling of the initial fully coupled state alone and on the resolution of the work
distribution depending on the number of independent NE trajectories. With this regard,
I show that the reliability and accuracy of the unidirectional estimate of the decoupling
free energies, based on the production of few hundreds of NE independent sub-nanoseconds
unrestrained alchemical annihilation processes, is a direct consequence of the funnel-like
shape of the free energy surface in molecular recognition.
THE STATISTICAL-THERMODYNAMIC BASIS FOR NON COVALENT BIND-
ING
The statistical mechanics foundation for the non covalent binding in drug receptor systems
in solution is based on the assumption that in the following chemical equilibrium
R + L ⇀↽ RL (1)
the complex, RL, behaves as distinct chemical species[41] with its own chemical potential,
exactly as the well defined chemical species R and L. Because of the intrinsic weakness of
the non bonded interactions (from few to few tens of kBT ), the partition function of the
complex R-L must rely on the definition of the configurational quantity I(r,Ω), with r and
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Ω being the translational and orientational coordinates of the ligand relative to the receptor.
I(r,Ω) is equal to 1 where the complex is formed and 0 otherwise.[8, 41–43] In the infinite
dilution limit, the equilibrium constant for the reaction of Eq. 1, K = [RL]
[R][L]
, can be defined
in terms of the canonical statistical average 〈I(r,Ω)〉V |limV→∞.[42] The quantity 〈I(r,Ω)〉
tends to zero at infinite dilution, such that the product 〈I(r,Ω)〉V tends to the equilibrium
constant as V tends to infinity:
K ≡ 〈I(r,Ω)〉V |lim→∞ = V
∫
I(r,Ω)e−βw(r,Ω)drdΩ∫
e−βw(r,Ω)drdΩ
=
1
8pi2
∫
I(r,Ω)e−βw(r,Ω)drdΩ (2)
where w(r,Ω) is the potential of mean force (PMF) for the {r,Ω} ligand-receptor confor-
mation. In deriving the last equation, we have used the fact that limV→∞
∫
e−βw(r,Ω)drdΩ =
8pi2V , as the PMF w(r,Ω) is non zero only in a limited volume where the RL complex exists
and zero otherwise. Eq. 2 is sometimes written as an integral restricted to the so-called
binding site volume Vsite
1
8pi2
∫
Vsite
e−βw(r,Ω)drdΩ. (3)
The equilibrium constant K for the reaction R + L ⇀↽ RL has the dimension of a volume
and is a true physical observable, usually accessed by measuring some spectroscopic signal s
that is proportional to the fraction of bound receptors (binding isotherm). [41] The binding
free energy is related to K via the equation
∆G = −kBT ln(K/Vref) (4)
where Vref is the reference volume in units consistent with the units of concentration in K,
e.g., 1 M or about 1661 A3/molecule for molarity units. As such, the free energy defined in
Eq. 4 is a purely conventional quantity, measured with respect to some state defined by the
reference molecular volume Vref . When the reference concentration is taken to be 1M (or,
equivalently, the molecular volume is 1661 A˚3), ∆G corresponds to the standard binding free
energy, indicated with ∆G0.
In atomistic molecular dynamics simulations, the equilibrium constant can be directly
accessed by means of Eqs. 2 and 3 using PMF-based technologies[21, 44] or binding energy
distribution methods.[14] These techniques require a prior knowledge of the domain where
I(r,Ω) = 1. However, if the binding is tight, and if the domain is chosen large enough
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so as to include all states contributing significantly to the integral of Eq. 3, then the
equilibrium constant is independent, within certain limits, on the integration domain.[8, 14]
Alternatively, one can compute the free energy gain/loss in the formation/dissociation of
the complex RL starting from the unbound state in solution or viceversa.[21, 24, 35] In
reversible alchemical transformations, as we shall see later on in detail, the free energy cost
for bringing the ligand from the bound to the unbound state in solution is obtained by
constructing a thermodynamic cycle whereby the ligand, in two distinct thermodynamic
processes, is reversibly decoupled (i.e. brought to the gas-phase) from the environment in
the bulk and in the binding site. While the decoupling free energy of the ligand in the
bulk, ∆GL, bears no dependence on the reference state, when alchemically decoupling the
ligand in the complex, the computed free energy ∆GRL depends on the effective reference
concentration of (or volume available to) the ligand implied in the simulation.[8, 31, 43, 45]
For example, when the RL complex is unrestrained except for periodic boundary conditions,
the volume available to the ligand is apparently that of the simulation box[21, 31, 32, 45].
Alternatively, one could allow the ligand in the bound state to move within an effective
volume set by a translational and rotational restraint potential[8] possibly matching the
region where the function I(r,Ω) is equal to 1. Whatever the approach adopted, in order
to make the computed dissociation free energy ∆Gsim = ∆GRL −∆GL independent of the
simulation conditions, a standard state correction (SSC) must be added such that
∆G0 = ∆Gsim + kBT ln
(
Vref
V0
)
+ kBT ln
(
ξref
8pi2
)
. (5)
The second and third terms in Eq. 5 may be viewed as the reversible work to bring the
volume and the solid angle available to the ligand in the simulation of the bound state
to that of the standard state V0 = 1661 A˚
3 and ξ0 = 8pi
2, respectively.[8] Eq. 5 is valid,
provided the alchemical transformation is done reversibly, that is, each intermediate state
along the alchemical decoupling coordinate must be at equilibrium, sampling canonically all
the configurations of the ligand contributing to the integral of Eq. 2. In the unrestrained
alchemical approach (Vref = Vbox and ξref = 8pi
2)), full canonical sampling at small λ is
pathologically difficult,[45] but also in the constrained variant, the restraint can be unin-
tentionally implemented in a such a way that some important orientations contributing to
Ii(r,Ω) are rarely accessible or poorly sampled in the time of the simulation. Thus, the lack
of dependence of ∆Gsim on Vref , sometimes observed in reversible alchemical simulations,
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indicates a problem, typically a convergence issue, such as the ligand not sampling the full
available phase space.
The elementary theory sketched out above works very well if the ligand behaves as an
entity performing small librations in a regular and smooth potential set by the surrounding
receptor. In the real world of drug-receptor binding processes, the potential in the binding
site can be very rugged, characterized by many local energy minima along complex ro-
vibrational collective coordinates. Energetically distinct conformations are very challenging
in equilibrium based MD techniques, as the final result may depend on the chosen initial set
up of the simulation.[14, 33] In the simple language of docking, we say that the ligand can
adopt different possible conformational “poses” with different scoring functions. Let’s now
assume that the ligand can occupy the binding site region, the so-called “exclusion zone”
in the receptor[41], with different orientations. We can hence define non overlapping step
functions of the kind Ii(r,Ω) (where the index i label the (RL)i orientational pose) in such
a way that I(r,Ω) =
∑Np
i Ii(r,Ω), with Np being the number of poses. In this manner, the
equilibrium concentration of the bound species RL detected by the signal s (that is assumed
to be unable to discern orientational poses in the exclusion zone) is given by
[RL] =
Np∑
i
[(RL)i] (6)
The species (RL)i, each defined by its own Ii(r,Ω) function, are subject to the simultaneous
equilibria
R + L ⇀↽ (RL)i i = 1, 2, ...Np
R + L ⇀↽ RL (7)
From Eq. 6 we trivially obtain that the overall equilibrium constant for the reaction
R + L ⇀↽ RL can be written as K =
∑Np
i Ki, with Ki =
[(RL)i]
[R][L]
being the equilibrium constant
for the complex in the i-th pose. Using Eq. 4, we may thus define the standard binding free
energy for pose i as ∆G0i = −kBT lnKi where Ki is expressed in molarity and a standard
state concentration of 1M is implied. Now, the molecular recognition machinery in biologi-
cal system works well because very often one particular pose is preferred with respect to all
others. If we set ∆G01 as the most stable pose among the Np possible ligand bound states,
then, using Eqs. 4 and 6 we can write
e−β∆G0 = e−β∆G10(1 +
Np∑
i=2
e−β∆G
i
1) (8)
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where we have defined the relative free energy difference ∆Gi1 = ∆G0i − ∆G01, i = 2..Np
between pose i and the most stable pose (i = 1). Note that the positive quantity ∆Gi1 ≡
−kBT ln KiK1 , referring to a process involving no changes in the number of species, bears no
dependence on the standard state. If all these relative free energies ∆Gi1 are worth several
kBT such that
∑Np
i=2 e
−β∆Gi1  1, then taking the logarithm of Eq. 8 one may write
∆G0 = ∆G10 − kBT
Np∑
i=2
e−β∆G
i
1 ' ∆G10 (9)
where we have used the fact that log(1 + x) ' x for x small. Eq. 9 says that, if one of
the poses is much more stable than all the others, then the overall standard binding free
energy in the drug-receptor system is dominated by that of the most favorable pose. Eq.
9 is indeed at the very heart of molecular recognition in biological systems. Eq. 9 is also
central, as we shall see in the following, in the NE theory of alchemical transformations since
when it holds, a very simple and unbiased estimate of ∆G10 may be derived from the work
distributions obtained in the NE trajectories.
REVERSIBLE ALCHEMICAL TRANSFORMATIONS IN DRUG RECEPTOR
SYSTEMS
As previously outlined, in the alchemical method, the absolute standard dissociation free
energy for the reaction RL ⇀↽ R + L may be recovered as the difference between the de-
coupling free energy of the ligand in the binding site and in the bulk solvent.[18] In either
processes, the free energy along the non physical path between the fully coupled state and
the decoupled states, with Hamiltonians H(x, λ)λ=1 and H(x, λ)λ=0 respectively, is com-
puted by discretizing the λ parameter in a number of Nλ intermediate states λi in the [0,1]
interval and by running a standard MD simulation for each of these states. The switching off
protocol of the ligand-environment interactions may vary from system to system although
there is a general consensus for first turning off the electrostatic interactions followed by the
Lennard-Jones atom-atom terms supplemented with a soft-core potential[46, 47] to avoid
catastrophic numerical instabilities when approaching to λ = 0. The reversible work of
the whole process can be obtained by appropriately summing up the individual free en-
ergy differences between neighboring λi states evaluated using either TI or FEP techniques.
In FEP, these differences are computed exploiting the superposition of neighboring po-
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tential energy distribution functions and implementing the Zwanzig formula[27] such that
∆Gf = −kBT ∑N−1i=1 〈e−β(Hλi+1−Hλi )〉λi with λ1 = 1 and λN = 0. In the decoupling pro-
cess of the bound state RL, the ligand, for each λi state, must sample all the attainable
conformations for the given Hamiltonian H(x, λi), including all secondary poses of the kind
(RL)j, j = 2, 3.. (see Eqs. 6-9). When λi is approaching to zero, the ligand may occasionally
leave the receptor, severely slowing down the convergence.[45] Therefore, when the ligand
is decoupled in the bound complex, usually it is common practice to impose a geometrical
restraint in the simulations so as to avoid the “wandering ligand problem” related to the
choice of Vref = Vbox.[8, 14, 17] The free energy cost of imposing the restraint, the so-called
“cratic” free energy[48], corresponds to the SSC discussed in Eq. 5. The SSC, stemming
from the restraint volume Vref , may be evaluated analytically[8, 48], or numerically,[17] de-
pending on how the restraints are imposed. Decoupling with restraints is often referred as
Double Decoupling Method[8] (DDM) while the unrestrained variant is known as double
annihilation method (DAM).[18, 37] In modern DDM implementation,[17] the translation
and rotational restraints, that force the ligand to explore a restricted orientational and po-
sitional space in the binding region, are progressively enforced/removed while the ligand is
being decoupled/coupled. Hence, each λi point in the [0,1] interval is actually characterized
by a potential coupling parameter λCi and by a restraint λ
R
i state. If each of the λi inde-
pendent simulations in the [0,1] interval has reached convergence, canonically sampling all
conformations that are attainable at the Hamiltonian H(x, λCi , λ
R
i )), then the free energy
computed in either directions (decoupling or coupling) must be identical and independent of
the initial set up of the system. When applying FEP to reversible alchemical transformations
is common practice[17, 34, 49] to evaluate the free energy difference between neighboring
states using bidirectional estimator.[28, 29] One can in fact define a “reverse” free energy
estimate as ∆Gr = kBT
∑N
i=2〈e−β(Hλi−1−Hλi )〉λi that must coincide for each λi point with the
forward estimate ∆Gf if equilibrium is reached everywhere along the alchemical coordinate.
The forward and reverse estimate in the λ interval (0,1) can be combined using the Crooks
theorem[40] and the Bennett acceptance ratio.[28] The manifestation of a hysteresis is usu-
ally syntomatic of lack of complete convergence. The latter is often related to the presence of
secondary poses (RL)i that may emerge especially at small λ values,[14, 33] when most of the
ligand-environment interaction has been switched off and barriers between alternate ligand
conformations/poses are smoothed. Kinetic traps provided by alternate poses may degrade
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the overlap between energy distributions of neighboring λi states, making the convergence
slow and uneven in the [0,1] interval.[36] To overcome this serious problem and unpredictable
behavior, in a parallel environment, alchemical transformations can be coupled to General-
ized Ensemble techniques whereby each replica of the system performs a random walk in the
λ domain with λ moving according to a Metropolis criterion, so as to make the λ probability
distribution flat on the whole [0,1] λ interval. These methods are termed λ-hopping schemes
and use either Hamiltonian Replica Exchange (HREM)[22], Serial Generalized Ensemble
(SGE) methodologies[50] or Adaptive Integration Schemes (AIM) [15, 33] and are all aimed
at defeating the convergence problems induced by the existence of meta-stable conforma-
tional states of the bound ligand along the alchemical path. In the HREM implementation,
no bias potential is needed in the transition probability, while in SGE or AIM, the bias
potential (i.e. an estimate of the free energy difference between neighboring λ windows) is
evaluated on the fly using the past history produced by all replicas.[50]
When different poses of the ligand in the binding site are separated by energy barrier
significantly higher than kBT , or for bulky ligands characterized by a manifold of conforma-
tional states, λ-hopping schemes may be non resolutive, still being plagued by convergence
issues.[33] For example, for a ligand as simple as phenol in Lysozime, convergence of the
decoupling free energy starting form a random pose may take as much as one nanosecond of
parallel simulation, even adopting a very fine grid when approaching to the decoupled state
λ = 0. [14] In the Thrombin-CDB complex[33] after about five nanoseconds of λ-hopping
simulation, convergence is not even in sight.[33] There are finally some pathological examples
where even λ-hopping schemes exhibit a marked initial pose dependence, like in the BACE1
complexes.[33, 51] The relative free energy of the BACE-24 and BACE1/17a systems may
differ by as much as 4 kcal mol−1 with two possible symmetrical orientation of a phenyl ring
of ligand 24 bearing a bulky substituent, whose size makes virtually impossible the flipping
of the ring in the binding site. In that case, even with the use of soft-core potentials, no
mixing whatsoever of the two poses at any λ state can be observed. One obvious way of
circumventing the lack of mixing in these cases is of course that of increasing the density
of λ states near the critical points of the λ path, correspondingly increasing the number
of replica and the cost of the simulation. Alternatively, as proposed in Ref. [33], one can
supplement the λ-hopping method with ad-hoc Hamiltonian scaling schemes on appropriate
collective/conformational coordinates of the ligand. These latter approaches, however, while
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preserving the efficiency of the alchemical calculation, are not general as they require prior
knowledge of the topology of the barriers and of the kinetic traps preventing the mixing
between the competing poses.
Summarizing, we may state that the real problem in reversible alchemical simulations is
related to the fact that it is not yet available a universal protocol for minimizing the statistical
uncertainty of calculations performed along an alchemical path. Uncertainty may depends
critically on the specific subsets of the λ path where activated collective coordinates, possibly
induced by the imposed restraints, can cause the insurgence of kinetic traps degrading the
energy overlap of neighboring λ states. With this regard, it has been pointed out that
minimizing the overall statistical uncertainty is equivalent to minimizing the thermodynamic
length, that is, of choosing the λ alchemical protocol so that the total uncertainty for the
transformation is the one which has an equal contribution to the uncertainty across every
point along the alchemical path.[36] The quest for the optimal path in alchemical reversible
transformations is intimately connected to the necessity of having an a priori estimate of
the accuracy in binding free energy evaluation. The latter is indeed an essential requirement
in the development of a second generation high throughput virtual screening tool in drug
discovery.[24] In the present stage, in spite of the many noticeable efforts in this direction,
reversible alchemical transformations are still quite far form being that tool.[6, 33, 36] In
the following sections I shall discuss some aspects of the theory of non covalent binding
in the context of non equilibrium transformation, showing that fast-switching alchemical
simulations[38] may provide a reliable and efficient instrument in drug discovery.
NON-EQUILIBRIUM THEORY OF ALCHEMICAL TRANSFORMATIONS IN
NON COVALENT BINDING
Basic theory
The requirement of an equilibrium transformation along the entire (0,1] semi-open in-
terval is lifted altogether in the recently proposed Fast Switching Double Annihilation
Method.[32, 38] FS-DAM implies an equilibrium sampling only on one extreme of λ [0,1]
interval, i.e. at the fully coupled states of the complex and of the free ligand in solution at
λ = 1. Once the initial states have been somehow prepared, several fast non equilibrium
11
trajectories (Nτ ) are launched in parallel with zero communication overhead by switching
off the ligand-environment interactions in a protocol. The fast decoupling protocol, identical
for all trajectories, is analogous to that used in the reversible counterpart (i.e. we first switch
off the electrostatic interactions and then we turn off the dispersive-repulsive term using a
soft-core potential to avoid instabilities at low λ’s). The duration τ of the Non Equilib-
rium experiments (τ -NE) may last from few tens to few hundreds of picoseconds depending
on the size of the ligand.[39] The annihilation of the ligand (in the complex or in bulk)
is conventionally taken to be the forward process.[52] The non equilibrium annihilation or
forward work, W1→0, done in driven τ -NE experiments starting from canonically sampled
fully coupled states with a common time schedule, obeys the Jarzynski theorem[53]
e−β∆G1→0 = 〈e−βW1→0〉 =
∫
P (W1→0)e−βW1→0dW1→0 (10)
with ∆G1→0 being the annihilation/forward free energy. For the annihilation of the complex,
the free energy must include a standard state correction that I shall discuss in detail below
in this section. The Jarzynski formula, Eq. 10, is of little practical use for evaluating ∆G1→0
since it relies on an exponential average over the distribution P (W1→0) on its left tail, i.e.
a statistics that is both inherently noisy and biased, even if the spread of the work data
is only moderately larger than kBT .[54–58] In case of Gaussian work distributions for the
(forward) annihilation process, the Crooks theorem[40],
PAB(W1→0)
PBA(−W0→1) = e
β(W1→0−∆G1→0), (11)
imposes that the underlying reverse work distribution PBA(−W0→1) for the fast growth
process must also be Gaussian with the same variance σ and with mean work given by
〈−W0→1〉 = 〈W1→0〉−βσ2,[32, 52, 54, 56, 59, 60] hence providing an unbiased unidirectional
estimate of the annihilation free energy based on the forward process alone of the form
∆G1→0 = 〈W1→0〉 − βσ
2
2
(12)
where the first two cumulants 〈W1→0〉 and σ are both a monotonic functions of duration
time τ of the NE process.[61, 62] The term βσ
2
2
represents the mean dissipation during the
τ -NE transformation. In this regard, it has been observed[39, 59, 63] that the work distri-
bution obtained in fast τ -NE annihilation/creation experiments of small to moderate size
organic molecules in polar (water) and non polar (octanol) solvents has a marked Gaussian
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character and that the corresponding dissipation is surprisingly small. Hydrophobic or polar
molecules, annihilated/created in explicit water or octanol in times as short as 63 or 180
picoseconds, consistently exhibit[39] dissipation energies ranging from 1 to 2 for kcal mol−1
for water and from 2 to 4 for kcal mol−1 for octanol. The corresponding forward and reverse
distributions, PAB(W1→0), PBA(−W0→1), have a high degree of superposition and are strik-
ingly symmetrical with respect to the free energy ∆G1→0 in all analyzed case, as predicted
by Eq. 11 for Gaussian distributions. The Gaussian nature of the annihilation/creation of
small molecules in water may be quantified by the cumulants of the distribution of order
higher than two, that according to Marcinkiewicz theorem[64] should all be equal to zero.
When the dissipation is small, i.e. the spread of the distribution is limited, the Gaussian
estimate Eq. 12 is astonishingly robust.[32, 38] in Table I I report results for the decoupling
〈W1→0〉 ∆G1→0 (Eq. 12) ∆G1→0 (Eq. 11)
Benzene 1.75 ± 0.09 0.87 ±0.14 0.79 ±0.04
Benzamide 11.15 ± 0.16 9.95 ±0.24 9.78 ±0.07
Ethanol 4.39 ± 0.05 3.80 ±0.04 3.80 ±0.04
Pentane -1.59 ± 0.06 -2.52 ±0.08 -2.56 ±0.05
TABLE I: Decoupling mean work and corresponding free energies (in kcal mol−1) for some polar
and apolar molecules computed using the work distributions reported in Figure 5 of Ref. [39]
free energy of drug-size molecules in water using the work data obtained in Ref. [39] for
the fast switching annihilation of a set polar and non polar molecules in water solvent in
standard conditions. The overall NE process lasted in all cases only 63 picoseconds and
the work distributions were obtained using 256 NE annihilation/growth works. In Table
I, the Gaussian estimate using Eq. 12 on the decoupling distribution reported in Figure 5
of Ref. [39] is compared to the bidirectional estimate (in bold font) obtained by applying
the Crooks theorem and the Bennett acceptance ratio. Remarkably, the fast annihilation
Gaussian estimates of the solvation free energies are practically coincident with the maxi-
mum likelihood Bennett-Crooks bidirectional estimate confirming the reliability of Eq. 12
in fast switching alchemical transformations in water solvent. Regarding the errors reported
in table I for the Gaussian estimate, it should be remarked that the variance in 〈W 〉 and σ2
for normally distributed samples follows the ancillary t-statistics[65] and is proportional to
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σ(τ)/(Nτ )
1/2 and σ2(τ)/(Nτ )
1/2, respectively where σ(τ) is the τ -dependent spread of the
underlying normal distribution. So, if σ is of the order of few kcal mol −1 and if Eq. 12
holds, only few hundreds trajectories are needed to get an error on the free energy below 1 kcal
mol−1. Unlike in reversible alchemical transformations, in their NE variant the overall error
can therefore be very naturally and reliably computed via standard block-bootstrapping
from the collection of Nτ NE works. In Table I, for example, the errors were computed
using random bootstrap samples with 128 work values, taken from the pool of 256 works.
Moreover, reducing the number of NE trajectories by a factor of G amplifies the error on
〈W 〉 and σ2 only by G1/2 making Gaussian based estimates extremely robust and reliable
even with a very small number of sampling trajectories.[32] The Gaussian shape in the rapid
annihilation of the ligand (in the bound or in the unbound state) is a natural consequence
of the time scale used in the annihilation (few tens to few hundreds of ps) of ligands in
standard conditions. As we shall discuss in detail further below, such time scale is way too
fast to allow extensive conformational sampling while λ is continuously decreased, but is
slow compared to the time scale of the modulating vibrational motions of the atoms sur-
rounding the annihilating ligand. In this way, the energy change at a given time t during
the driven τ -NE process depends to a very good approximation only on the alchemical state
(i.e. on the instantaneous value of λ(t)) at that given time) as in Markovian memory-less
processes.[39, 56]
Free energy estimates for a mixture of Gaussian processes
Eq. 12, based on a single symmetrically related forward and reverse work distributions,
implies that the τ -NE process connects two well defined thermodynamic states, each defined
by a single free energy basin. This could be the case for the process of fast annihilat-
ing/growing of a small and relatively rigid molecule in a solvent. When the initial and/or
the final thermodynamic states are characterized by a manifold of free energy basins with
uneven well depth, (like for the many alternate poses of a ligand on a receptor or for the
misfolded states of a protein) then Eq. 12 is no longer valid and the observed forward
and reverse work distribution can be strongly asymmetrical.[52] In Ref. [32] it was shown
that, in systems characterized by a principal free energy basin and a manifold meta-stable
states on one or both end of the τ -NE process, then the asymmetrical forward P (W1→0)
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and reverse distributions P (−W0→1) can be rationalized in terms of a mixture of an equal
number of, say N , Gaussian functions of identical width in either direction, with first or-
der τ -dependent forward cumulant, µi, and weights, ci, regulated by a generalization of the
Crooks theorem-based Eq. 12:
∆G1→0 = −kBT ln
N∑
i
cie
−β(µi−βσ
2
i
2
) (13)
In the above equation, the forward ci weights satisfy the constraint
∑
i ci = 1 and the reverse
first order cumulants, νi and weights, di, are related to the forward counterpart by
νi = µi − βσ2i (14)
di = e
β∆Ge−β(µi−
βσ2
i
2
)ci (15)
In other words, the Crooks theorem, Eq. 11, imposes that, if in one direction of the τ -NE
process the work distribution happens to be given by a combination of N normal distribu-
tions, somehow connected to the existence of a manifold of free energy basins, it must be
so in the reverse process as well, albeit with different combination coefficients given by Eq.
15. Eqs. 13-15, with N = 2 explains surprisingly well the striking asymmetry observed in
systems where one direction of the τ -NE experiment (forward and/or reverse) envisages the
entrance in a funnel, like in the folding of a small poli-peptide[32, 52, 62] or, possibly, in the
docking of a drug on a receptor. To see why in this latter case, suppose that on one end of
the τ -NE process we have only one possible free energy basin (say the uncoupled state R +
(L)gas−phase at λ = 0), and on the other end (say the coupled state RL at λ = 1) one of the
many basins has a disproportionate Boltzmann weight with respect to weight of the others
all lying several kBT . According to Eq. 9, the overall weight of these secondary poses is
given by Ws =
∑Np
i=2 e
−β∆Gi1 . Then, provided that 1/Nτ > Ws, all Nτ trajectories, starting
form the equilibrium fully coupled state with λ = 1, should include sub-states sampled only
in the principal basin. All these τ -NE trajectories, starting form the principal pose, end up
into the same state corresponding to the single free energy basin at λ = 0 of the free receptor
and of the unbound ligand. The resulting forward work distribution should hence appear
quasi Gaussian with a τ -dependent dissipation βσ2(τ)/2 and with inappreciable contamina-
tion on the left tail of the distribution due to normal components related to the so-called
“shadow states”.[32] These shadows states can be only explored and perceived as end τ -NE
states in the reverse process where, for short τ , most of the final τ -NE poses would be clearly
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sub-optimal. As stated in Ref. [32], because of the mathematical structure of the Crooks
theorem for Gaussian mixtures, shadow states in the τ -NE reverse process undergo exponen-
tial amplification (see Eq. 15). From a physical standpoint, in the reverse process, starting
from the single-basin state, the components of the arrival multi-basins thermodynamic state
can be explored and detected because of the extra energy provided by the dissipation that
allows to overcome the barriers between the basins.
Standard state correction (SSC) in non equilibrium unrestrained alchemical simu-
lations
As previously discussed, unconstrained reversible DAM provides a dissociation free energy
∆Gsim = ∆GRL − ∆GL that in principle should depends on the box volume via Eq. 5,
but in the practice results in many cases apparently independent on it.[18, 34, 35, 37] It
has been argued[8, 21, 45] that such apparent independence on the simulation conditions
arises since it is difficult to reach full convergence in a simulation time of the order of the
nanosecond at small λ’s where the ligand may leave the binding site and start to explore
orientationally and translationally disordered unbound states. In effect, the two decoupling
processes, leading to ∆GRL and ∆GL, are both performed in the same way: one must switch
off the ligand interactions from environments of comparable atomic density and having
a common maximum distance range of the order of 10:15 A˚. This given, it seems quite
unreasonable that in just one of these processes, the annihilating free energy is so dependent
on the volume or on the time scale of the simulation. The stubborn apparent independence
of the computed decoupling free energy for the bound state ∆GRL on the volume of the
simulation box and on the length of the simulations has often lead[34, 35, 37] to essentially
identify ∆GDAM = ∆GRL−∆GL with ∆G0 itself, even negating the very existence[34] of the
standard state correction Eq. 5. The mystery in DAM unrestrained simulations involving
the inability of detecting a measurable dependence of ∆GDAM on either Vbox or the simulation
time, eventually leaded to the development of the DDM reversible theory,[8] where, in the
annihilation of the ligand in the complex, Vref and ξref are imposed using a biasing potential
impacting on the standard state correction via Eq. 5. Tight biasing potentials allow a safe
sampling at any λ in most cases within nanoseconds of simulation at the price of artificially
modifying the receptor exclusion zone, possibly inhibiting the access to important part of
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Vsite contributing significantly to the integral of Eq 3. For infinitely loose biasing potential,
DDM clearly must coincide with DAM, provided that we set Vref = Vbox and ξref = 8pi
2,[21]
leading to the relation ∆GDAM = ∆G0 − kBT ln
(
Vref
V0
)
, in principle correct, but consistently
contradicted in the simulation practice. As we shall see in the following, the identification of
∆GDAM with a volume independent system quantity related to ∆G0 rather than ∆Gsim in
DAM can be assumed to be legitimate if unrestrained DAM is conceived as a non equilibrium
experiment (NE-DAM), with many long NE trajectories producing a very narrow, apparently
Gaussian, work distribution, with a shadow component at a much lower energy dependent
on the simulation volume, obeying the Crooks theorem-derived Eq. 13. In other words, the
true volume-dependent value of ∆Gsim in DAM is computationally unattainable in a single
simulation.
In principle, one could straightforwardly implement a NE variant of DDM using a re-
strained potential that keeps the volume in the binding site during the decoupling process,
as it occurs in reversible DDM. However, a restraint potential in NE-DAM is not necessary
neither desirable. As previously stated, the restraint potential is introduced in equilibrium
alchemical transformation to limit the sampling of the ligand accessible r,Ω space, in order
to make the transformation reversible. In NE-DAM or FS-DAM the decoupled states in the
semi-open interval (1,0] are by definition non equilibrium states with no specific require-
ments of sampling, except for those dictated by the initial bound configurations at λ = 1
(the only states sampled at equilibrium) and by the time τ of the NE experiments. More-
over, in the annihilation of the ligand in the bound state, the final available translational and
rotational volumes for the ligand depend on the time τ of the NE simulations.[38] Borrowing
the notation from the equilibrium relation Eq. 5, we define these NE volumes as V (τ) and
ξ(τ). Given a forward τ -NE transformation, Eq. 11 applies if the process can be inverted.
While for the ligand in the bulk the decoupling process can be straightforwardly inverted
with a τ -lasting inverted-schedule growth process, for the ligand in the complex, the reverse
(growth) process is more elusive. As stated in Ref. [38], an hypothetical reverse process of
the same duration τ with inverted time schedule from the decoupled state of the complex
to the fully coupled state should be performed by switching on first the dispersive-repulsive
(soft-core) potential of the ligand and then the electrostatic interaction, with the gas-phase
decoupled ligand in initial positions and orientations relative to the receptor sampled ran-
domly from the NE volumes V (τ) and ξ(τ) found in the forward transformation. By virtue
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of the Crooks theorem. Eq. 11, this reverse work distribution P (−W0→1) must cross the
forward counterpart at a τ -dependent free energy ∆GRL(τ) = ∆GRL(V (τ), ξ(τ)). To get rid
of the τ -dependence in ∆GRL we can imagine to do the forward NE transformation in two
step. In the first stage, we switch off the ligand-environment interactions almost completely
up to an arbitrarily small λτ = δλ in the time τ , obtaining basically the same forward work
distribution P (W1→0) of the complete τ -NE process. Thanks to the soft-core potential, when
λ is infinitesimally small, the ligand does not sense anymore the environment and starts to
move ballistically in a random direction with random translational/rotational velocities. In
a second step, doing practically no work, we finally switch off the residual interaction in a
time τbox long enough so that the Nτ+τbox end states get randomly distributed in the whole
simulation box. The reverse τbox + τ -NE process, in this case, is essentially equivalent to
the switching on of the ligand in a time τ starting from a random position and orientation
within the simulation box. With this time protocol, ∆Gsim, like in DAM, must be a function
only of Vbox, no longer depending on τ , so that
∆Gsim = ∆GRL −∆GL = ∆G0 − kBT ln Vbox
V0
(16)
In the reverse τ¯ -NE process, in most of the NE-trajectories, the ligand is switched on in
the bulk solvent or in a sub-optimal random pose on the receptor surface yielding a mean
work (with inverted sign) that is substantially smaller than the mean work obtained in
the forward transformation. The distance between the forward and reverse distribution
is of the order of the Vbox dependent dissociation free energy so that, for tight binding
ligand, P (W1→0) and P (−W0→1) have a negligible overlap.[38] In the Figure 1, I report,
as an illustrative example, the forward and reverse work distribution in a real unrestrained
fast switching NE-simulations, that is the annihilation/growth of the Zinc(II) cation in the
Zinc(II)-MBET306+ complex in explicit water in standard condition in a cubic MD box of
volume Vbox ' 15000 A˚3. The distribution were obtained using 256 annihilation/growth
runs each lasting 90 ps. Further details on the simulations are given in Ref.[38] On the
right (solid black line), we have the annihilation work distribution P (W1→0) of the principal
bound state of the Zn-MBET306+ bound species. On the left (dashed red line), I report
the reverse distribution P (−W0→1) corresponding to the growth of the Zinc(II) cation from
a random position in the MD box in presence of the MBET306−1 receptor, where the most
likely final NE-state corresponds to an unbound Zinc(II) in the bulk solvent. The small
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FIG. 1: Forward (solid, black) and reverse (dashed, red) work distribution in the Zn(MBET306)−1
complex in water calculated using fast switching NE simulations.
features of P (−W0→1), at about 410:415 kcal mol−1 with overall weight proportional to with
Vsite/Vbox, corresponds to a few trajectories yielding a work that is related to the secondary
poses of the Zn(II) on the MBET306− anion.
The pattern shown in Figure 1 closely resembles that seen in systems where one direction
of the τ -NE experiment envisages the entrance in a funnel, like in the folding of a small poli-
peptide.[32] The entrance in the exclusion zone (that for the case of the Zn(MBET306)+
complex reported in Figure 1 corresponds roughly to the volume surrounding the central
tartrate core of the molecule), via fast-growth from randomly sampled positions in a volume
that is much larger than Vsite, is a far more dissipative process than the alchemically driven
escape of the ligand from the binding site. Based on this analogy, we make the Ansatz
that the forward decoupling work distribution P (W1→0) for tightly bound ligand receptor
system is made of essentially of one principal normal distribution relative to the starting
stable pose of the ligand in the exclusion zone, N(W,µ, σ), and by a negligibly small volume-
related work distribution N(W,µbox, σbox) due to sub-optimal poses or unbound states that
could be detected in the reverse recoupling process:
P (W1→0) = (1− c)N(W,µ, σ) + cN(W,µbox, σbox) (17)
In Eq. 17 we have therefore that c  1. With this regard, it is important to realize that,
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the second normal component depending on µbox, while negligible in shaping the forward
distribution, because of the Crooks theorem Eq. 11 gets exponentially amplified in the
reverse process (see Eq. 15). We further assume, in Eq. 17, that 0 < µbox < µ and σ ' σbox.
The first assumption simply says that the non covalent complex exists, and hence one must
do work to switch off the interaction with the environment and that this work must be
larger than the mean work µbox done to switch off the interaction with the environment
when the ligand may no longer be in the exclusion zone. The second simplifying assumption
implies no loss of generality[32] and is based on the reasonable expectation that the mean
dissipation, βσ2/2, depends in essence on the particle density in the given thermodynamic
conditions and that therefore σ should be weakly dependent on the environment surrounding
the ligand. Given the forward distribution Eq. 17, the Crooks theorem, Eq. 13, imposes
that the reverse distribution,
P (−W0→1) = d N(W, ν, σ) + (1− d)N(W, νbox, σbox) (18)
is such that ν = µ− βσ2 and νbox = µbox − βσ2 (See Eq. 14). The weight d of the reverse
Gaussian normal component with mean ν in Eq. 18 equals the probability of growing the
ligand in the exclusion zone form a random position in the volume Vbox, i.e
d = Vsite/Vbox. (19)
If Vbox  Vsite, as it occurs in the simulation practice, then d is small and the principal com-
ponent of the reverse process is N(W, νbox, σbox). The volume dependent free energy ∆GRL
is found at the crossing point of the µ-related forward and reverse Gaussian component:
∆GRL = µ− 1
2
βσ2 + kBT ln
d
1− c
' ∆Gx + kBT ln d (20)
where in the last equation we have exploited the fact that c  1 and we have defined
∆Gx = µ − 12βσ2. For Gaussian NE processes, the quantity µ − 12βσ2 should be invariant
with respect the duration time τ of the experiment, always yielding the minimum reversible
work to do the transformation. As a matter of fact, if we make Vbox larger, we need to set
τbox larger but we clearly have no impact on the mean work µ done up to τ . So ∆Gx, unlike
the crossing point ∆Gsim, does not depend on the box volume. Using Eq. 19 we finally find
∆GRL = ∆Gx + kBT ln
Vsite
Vbox
(21)
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FIG. 2: Forward/decoupling (left) and reverse/re-coupling (right) NE alchemical process in drugs
receptor system. Six possible outcomes of NE trajectories are shown. The receptor is depicted in
blue with the a square-shaped exclusion zone to allocate the ligand corresponding to a single box
unit of the 2D-grid. The drug is red when is fully interacting with the environment and is light red
when is in the decoupled state. In the forward process on the left, all the Nτ equilibrium starting
configurations are in the bound state and the final states the ligand ends up in a random position
in the MD box. In the reverse process, the decoupled ligand is initially randomly distributed in the
box and ends in different unbound states or sub-optimal poses on the receptor. The probability
to end up in the correct bound state is given by the volume of the exclusion zone divided by the
total volume of the MD box, i.e. to 1/Ngrid.
= ∆Gx + kBT ln
Vsite
V0
− kBT ln Vbox
V0
(22)
By subtracting on both side of Eq. 22 the volume independent solvation free energy of the
ligand ∆GL and by using Eq. 16, we finally find that the standard dissociation free energy
in NE alchemical transformation is given by
∆G0 = ∆Gx −∆GL + kBT ln Vsite
V0
(23)
In deriving Eq. 23 from NE theory, DAM theory is somehow vindicated. The annihilation
free energy of the complex in DAM may be thought as being derived from a high number
21
of slow (ns time scale) quasi-equilibrium trajectories yielding a very sharp and normally
distributed ∆Gx plus a shadow state that could be visible only if one does the reverse
reaction, i.e. the switching on of the ligand in a random position of the MD box, in presence
of the receptor. In the context of NE thermodynamics, the DAM free energy ∆Gx is indeed
a system dependent quantity as conjectured in Ref. [34, 37] that needs only to be shifted
to match the SSC reference value by the kBT ln
Vsite
V0
. This correction for drug size ligand,
is actually very small. Using value of 10 A˚3 as the mean volume per atom in condensed
phases in standard conditions, we may estimate Vsite using the volume of the ligand itself,
obtaining a SSC correction ranging from -0.7:0.1 kcal mol−1.[37]
COMPETITIVE POSES AND CONFORMATIONAL SAMPLING IN NON EQUI-
LIBRIUM SIMULATIONS
We have seen that FS-DAM and DAM can be both embedded in the context of non equi-
librium transformations. FS-DAM and DAM differ only in the speed of the NE process, fast
in FS-DAM, very slow in DAM. In both cases the distribution P (W1→0) for the annihilation
of the ligand is normal with insignificant contamination by normal components of shadow
states due to poses outside the exclusion zone or to unbound states. The distributions rel-
ative to these shadow states are exponentially amplified via Eq. 15 in a hypothetical (and
unnecessary) reverse process where we grow the gas-phase ligand in a random position in
the MD box and with random orientation with respect to the receptor, producing, when
dealing with tight-binding ligand, a main normal component N(W, νbox) with no overlap
with the forward Gaussian component N(W,µ) as shown in the example reported in Figure
1. We have also seen, in the preceding section that, given a spread of the work distribu-
tion of few kcal mol −1 for speeds of the decoupling process lasting in the order of 50:300
picoseconds, few hundreds of τ -NE trajectories are sufficient for getting an accuracy within
0.5 kcal mol−1 in the dissociation free energy.[38] In the scheme reported in Figure 2 we have
implicitly assumed that the bound state free energy is independent of the orientation of the
ligand in the binding site. In reality, the ligand could be found in the exclusion zone with,
e.g., several competing and mutually exclusive orientational poses (or free energy basins),
with one of such poses being much more favorable than all the others (see Eq. 9). A mini-
mum relative free energy difference such that Mini 6=1(∆Gi1) > 3.72 kcal mol
−1 translates in
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FIG. 3: Schematic representation of the forward and reverse work distribution in the alchemi-
cal decoupling process for a ligand with one principal pose and with a secondary orientational
pose (see text for details). Normal components related to unfavorable ligand-receptor free energy
basins are exponentially amplified in a hypothetical reverse process (dashed, red line). Assum-
ing that the volume of the exclusion zone is such that Vsite ' V0, the example show a possible
P (W1→0), P (−W0→1) diagram for a ligand with a dissociation energy in the order of 20 kBT .
a probability ratio Pi/P1 < 1/512 and is hence sufficient to exclude all the conformations
due to the secondary poses i = 2..Np from the pool of the few hundreds starting states of
the bound complex randomly sampled out an equilibrium distribution. It follows that the
apparent distribution due to the Nτ trajectories is again, in essence, normal, although is
now made (in the limit Nτ → ∞ or for averages over infinite non overlapping bootstrap
Nτ samples) of three components, namely that due to the principal pose, that due to the
secondary poses in the exclusion zone with weight c2 = e
−β∆G21 < 1
512
and the shadow state
due to the sub-optimal poses on the receptor surface outside the exclusion zone or in the
solvent with even smaller weight cbox ' e−β∆G0 :
P (W1→0) = (1− c2 − cbox)N(W,µ1, σ) + c2N(W,µ2, σ) +
+ cboxN(W,µbox, σ). (24)
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where, for the sake of simplicity, we have assumed a pose independent spread/dissipation
σ for all τ lasting NE annihilation/growth processes. As already discussed, the Gaussian
nature of the annihilation work distribution is somehow guaranteed by the speed (few tens
of few hundreds of picoseconds) with which the alchemical decoupling is carried on allow-
ing only marginal mixing between the underlying free energy basins at the intermediate
NE λ states. This is clearly at variance with reversible transformations, especially when
implemented with λ-hopping schemes, that are introduced precisely to favor the canonical
mixing all along the alchemical coordinate. It should also be noted that λ-hopping schemes,
based on probabilistic criteria for the λ dynamics, are either at convergence or they are
incompatible with NE theory since they make the annihilation process not invertible. We
have seen that the νbox related coefficient, 1 − d, in the reverse distribution of Eq. 18 gets
exponentially amplified via the Crooks theorem-derived Eq. 15. By the same token, in a
hypothetical reverse process, the normal components due to secondary poses in the exclu-
sion zone are exponentially amplified via Eq. 15 so that the bound-stated related minor
peak at ν integrating to Vsite/Vbox (see Eq. 18 and Eq. 19) gets split in a left-most peak
due to the manifold of secondary poses and to a smaller peak due to the principal pose
whose height is proportional to the ratio ξ(Ω)/8pi2 where ξ(Ω) is the fraction the domain
{r,Ω} : I(r,Ω) = 1. On the overall, the Crooks theorem-related reverse distribution is of
the form
P (−W0→1) = d1 N(W, ν1, σ) + d2N(W, ν2, σ) +
+ (1− d1 − d2)N(W, νbox, σ). (25)
with d1 < d2 < (1− d1 − d2). In Figure 3 these concepts are schematized. The reverse dis-
tribution (dashed, red line) exhibits a principal left-most peak, νbox, due to the sub-optimal
poses off the binding site, an intermediate peak ν2 due a wrongly oriented poses in the bind-
ing site and a weak component due to the primary pose ν1 = ν that is strongly overlapping
with the forward apparently single component annihilation distribution. Assuming for the
sake of simplicity and without loss of generality that Vsite ' V0 such that ∆Gx ' ∆G0, the
crossing point of the forward and reverse distribution is again, as in Eq. 20, at the point
∆G0 + kBT ln d and again the free energy ∆G0 can be computed using the single Gaussian
unbiased estimate of Eq. 12. In order to convey the concept, the weight of the compo-
nents due to the bound states, ν1 and ν2 in the 3-G reverse distribution of Eq. 25 have
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been greatly exaggerated. Actually, the ratio Vsite/Vbox, i.e. the overall weight of the bound
states in the unrestrained reverse distribution for real drug-receptor system is expected in
the range Vsite/Vbox=0.01:0.001, implying that only few trajectories out of hundreds could
produce a work corresponding to a bound state, exactly as observed in the growth of the
Zinc(II) cation in presence of the MBET306− anion (see Figure 1). Besides, the peak relative
to the principal pose, ν1, is exponentially abated via Eq. 15 so that basically none out of
few hundreds reverse NE trajectories is expected to yield a work (with inverted sign) falling
near the forward distribution P (W1→0). Based on the reverse process shown in Figure 1
for a simple atomic ligand, we conclude that a hypothetical reverse process in unrestrained
NE DAM in real drug-receptor systems would systematically produce a forward and re-
verse distributions separated by a large gap, related to the dissociation energy itself, making
bidirectional estimates such as Bennett acceptance ratio unreliable.[32] The principal-pose
assumption in the bound complex, leading to Eq. 9, constitutes the thermodynamic basis
for molecular recognition. Most importantly, the existence of a pose with overwhelming
Boltzmann weight in the complex implies a nearly Gaussian distribution in the τ -NE decou-
pling of the ligand, allowing a reliable and unbiased estimate of the annihilation free energy
∆GRL to be obtained via the simple, unbiased Gaussian estimate Eq. 12. Such principal
pose must of course be known from the start to be able to sample the equilibrium initial
states at λ = 1 in the corresponding free energy basin via standard molecular dynamics.
Secondary poses can be checked in a similar manner, in a separate and independent NE
experiment by using initial states all sampled in the corresponding secondary free energy
basins. Again, if the NE simulations are so fast that only marginal mixing occurs among
poses during the decoupling of the ligand, then the absolute dissociation free energy, ∆Gi0
of the i-th secondary pose can also be determined using a simple Gaussian estimate, yielding
as a trivial byproduct, the relative free energy difference ∆Gi1 = ∆Gi0−∆G10, i.e the Boltz-
mann weight of the i-th pose relative to the principal pose, exp(−β(∆Gi0 − ∆G10). Such
an approach has been used successfully in Ref. [38] to derive the overall binding constant
in water of the complex of the Zinc(II) with the MBET306−1 anion, an inhibitor of the
Tumor necrosis factor α converting enzyme. In that study, Sandberg et al. examined via
NE unrestrained unidirectional simulations more than ten different poses of the cation on
the tartaric moiety of MBET306−.
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FAST SWITCHING CALCULATION OF SOLVATION ENERGIES ∆GL
In the complex, the preparation of the equilibrium starting states is an easy one. The
ligand, by filling the exclusion zone of the receptor, inhibits its conformational motion and
that of the protein residues delimiting the binding site, hence reducing the conformational
entropy of the complex. Once the Nτ NE independent trajectories from these states are
FIG. 4: Fast switching forward (dashed black) and reverse (dashed red) work distributions obtained
for N-Elte378 in water (Nτ = 512, τ=270 ps. The free energy was evaluated using Eq. 13 assuming
two normal components. Error bars reported on the fitted distributions (solid lines) were computed
by bootstrapping samples of 256 works.
launched, unlike in λ-hopping reversible DDM, we are no longer concerned with equilibrium
sampling. Each λ-driven trajectory ends up irreversibly in the NE final decoupled state pro-
ducing a mean work that depends chiefly on the enthalpy of the starting equilibrium state
and not on the intermediate states that are rapidly crossed. FS-DAM, like DAM, needs
also to annihilate the ligand in the bulk to get ∆GL and hence ∆G0 via Eq. 23. While
the calculation of ∆GL is computationally far less demanding than the decoupling free en-
ergy of the bound state, the starting equilibrium states of the free ligand in bulk, especially
when the ligand exhibits competing conformations of comparable free energies, should be
prepared with the due care. I report as an illustrative example the case of the N-Elte378
[(2S)-1-(2-oxo-2-phenylacetyl)-N-(3-phenylpropyl) piperidine-2-carboxamide], a tight bind-
ing synthetic ligand of the immunophilin FKBP12.[66]. N-Elte378, a conformationally dis-
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ordered molecule, can be characterized in water by a competition between extended and
compact conformations (see Figure 7 of ref. [66]), the latter being stabilized by persistent
stacking interaction involving the two terminal phenyl moieties. The starting equilibrium
configurations of N-Elte378 in water for the fast switching calculation of ∆GL in bulk are
taken from a Hamiltonian Replica Exchange simulation with torsional tempering reported in
Ref. [66]. Simulations details and methods can be found in Ref. [66]. The fast annihilation
(forward) works were obtained running, in a single parallel run, 512 NE-trajectories lasting
270 ps. During the NE process, the solute is linearly discharged in the first 120 ps, followed
by the switching off of 2/3 of the dispersive-repulsive interactions up to 150 ps. In the last
120 ps the residual Lennard-Jones interaction is finally switched off, using a soft-core reg-
ularization to avoid numerical instabilities near λ = 0.[46] The fast growth (reverse) work
from gas-phase N-Elte378 were collected with inverted time schedule using again 512 NE
trajectories. The parallel computations were done using the fast switching alchemy version
of the ORAC code[39, 67] in less than one wall-clock time hour. In Figure 4, I report the
computed forward and reverse work distributions for N-Elte378 in water (dashed lines) along
with the fitted distributions using Eq. 13 with two normal components (solid lines). Due to
the complex conformational manifold, and because of the significant mixing between confor-
mations during the 270 ps decoupling process, the annihilation work distribution in solvated
N-Elte378 does not appear as a simple normal distribution, roughly reflecting the bi-modal
structure observed in the probability distribution of the distance between the two terminal
phenyl moieties (see Figure 7 of Ref. [66]). Still, Eq. 13 explains very well the observed
strikingly asymmetrical forward and reverse distributions, that were fitted assuming two
normal components (N = 2 in Eq. 13). The errors bars on the fitted distributions and on
the hydration free energy are computed by block bootstrapping the collection of 512 work
using 40 samples with 256 works. The bidirectional free energy computed using the Bennett
acceptance ratio using the forward and reverse 512 works is computed at 11.02 ± 0.05 kcal
mol−1, comparing favorably with the estimate of 11.16 ± 0.16 kcal mol−1 based on Eq. 13.
CONCLUSIONS AND PERSPECTIVE
In this study I have revisited the theory of non covalent bonding in the evaluation of the
binding free energies in drug-receptor systems from a non equilibrium perspective. I have
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shown that, in the context of the alchemical approach, the dissociation free energy of the
complex can be effectively and accurately derived producing few hundreds of non equilib-
rium unrestrained trajectories starting from canonically sampled fully coupled bound states.
The inherent Gaussian nature of the probability of doing a work W at the end of the fast
annihilation process allows to recover the decoupling free energy using a very robust unidi-
rectional unbiased estimate. The fast switching double annihilation estimate (FS-DAM) is
based on the assumption that the forward annihilation and the hypothetical reverse growth
work distributions of the ligand in the complex and in the bulk are given by a mixture of
normal distributions with weights regulated by the Crooks theorem. The standard state
correction, related to the volume of the exclusion zone in the receptor, arises naturally in
non equilibrium alchemical transformations with no need for restraining the motion of the
ligand in the bound state. Non equilibrium unrestricted alchemical transformations elimi-
nate altogether the necessity for canonical sampling at intermediate λ states that constitutes
the major stumbling block in the reversible alchemical approach. In this regard, one of the
most critical aspects in reversible alchemical simulations, intimately related to the sampling
issue, is the need of minimizing the overall statistical uncertainty of the free energy evalu-
ation with respect to the alchemical protocol, that is, of equalizing the contribution to the
uncertainty across every point along the alchemical path. In FS-DAM, equilibrium sampling
is required at one single point along the alchemical path, at the fully coupled Hamiltonian.
As a consequence, the accuracy of FS-DAM free energies depends in a predictable way on
the resolution of the resulting work distribution, i.e. on the ratio of the spread of the work
distribution and on the number of NE independent trajectories. The Crooks theorem-based
estimate of the FS-DAM free energies relies on the determination of the first two cumulant
of a normal distribution, whose variance is subject to the ancillary t-statistics and is pro-
portional to σ(τ)/(Nτ )
1/2 and σ2(τ)/(Nτ )
1/2, where σ(τ) is the τ -dependent spread of the
distribution. Reducing the number of NE trajectories by a factor of G amplifies the error on
µ and σ2 only by G1/2 making FS-DAM estimates extremely robust and reliable even with
a very small number of sampling trajectories.[32]
As the NE-trajectories can be run independently, the FS-DAM approach can be straight-
forwardly and efficiently implemented on massively parallel platforms providing an effec-
tive tool for virtual screening in the drug discovery process. In the applicative companion
paper[68] of the present theoretical contribution, we apply the FS-DAM technology to a
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challenging drug-receptor system, the FKBP12 protein associated to the FK506 related lig-
ands, comparing performances and accuracy to the standard equilibrium approach. In that
study [68] we show that FS-DAM satisfactorily reproduces the experimental dissociation
free energies of several FK506-related bulky ligands towards the native FKBP12 enzyme in
a single massively parallel run in matter of few wall time clock hours on a High Performance
Computing facility. FS-DAM is finally used to predict the dissociation constants for the
same ligands towards the FKBP12 mutant Ile56Asp. The effect of such mutation on the
binding affinity of FK506-related ligands is relevant for assessing the thermodynamic forces
regulating molecular recognition in FKBP12 inhibition. Moreover, the binding affinities
of FK506-related ligands for the Ile56Asp FKBP12 mutant are, to our knowledge, not yet
available, exposing our FS-DAM predictions to experimental verification. Anticipating the
results presented in Ref. [68], we summarize in Table II performance and accuracy tests of
the FS-DAM method compared to the standard equilibrium approaches for the evaluation
of the dissociation constant of a drug-receptor pair in explicit solvent. These results are fully
Nτ Nλ Simulation time Mean error on
(ns per ligand) ∆G0 (kcal mol
−1)
FS-DAM 512 n/a 218 0.3
FS-DAM 256 n/a 149 0.7
FS-DAM 128 n/a 115 1.5
FEP[69] n/a 31 18000 1.5
FEP[70] n/a 33 400 4.5
FEP/BAR[34] n/a 32 900 3.0
FEP-restraint[71] n/a 25 250 1.5
TABLE II: Performances of NE FS-DAM and equilibrium FEP. Nτ and Nλ indicate the number
of independent NE trajectories (applicable in FS-DAM only) and the number of λ intermediate
states (applicable in FEP only). All data refer to the FKBP12 receptor[68] on per ligand basis.
detailed in Ref. [68] and show that FS-DAM outperforms FEP approaches,[34, 69, 70] both
in terms of precision/reliability and of CPU time. The efficiency, simplicity and inherent
parallel nature of FS-DAM, project the methodology as a possible effective tool for a second
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generation High Throughput Virtual Screening in drug discovery and design.
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